FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Machinaton	$D \subset$	20E 40	
Washington,	D.C.	20549	

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average burden										
hours per response	: 0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

					_														
Name and Address of Reporting Person* Cowie Robin Harper						2. Issuer Name and Ticker or Trading Symbol BIODESIX INC [BDSX]									5. Relationship of Reporting Person(s) to Issue (Check all applicable) Director 10% Owne				
(Last) (First) (Middle) 2970 WILDERNESS PLACE						3. Date of Earliest Transaction (Month/Day/Year) 08/08/2023									cer (give title Other (specify below) CFO, Sec'y & Treasurer				
SUITE 100						4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line)								oplicable					
(Street) BOULDER CO 80301						X Form filed by One Repo Form filed by More than Person											Ü		
(City)	(S	tate)	(Zip)			Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to											ded to		
											itions of Rule								
		Tabl	e I - N	lon-Deriv						, Di									
Date			2. Transact Date (Month/Day		Exec if any	ny ´				ies Acquired (A) or Of (D) (Instr. 3, 4 and		Benefi	ties cially I Following	6. Own Form: I (D) or I (I) (Inst	Direct ndirect tr. 4)	7. Nature of Indirect Beneficial Ownership			
									Code	v	Amount	(A) or (D)	Price		ed ction(s) 3 and 4)			(Instr. 4)	
Common Stock 08/08/2				08/08/2	023	23		M		11,575	A	(1)	13	135,112)			
Common Stock 08/09/20)23				S ⁽²⁾		1,789	D	\$1.3883	3 ⁽³⁾ 13	3,323	Ι					
Common Stock 08/10/20			023				S ⁽²⁾		1,788	D	\$1.2669	9 ⁽⁴⁾ 131,535)				
		Ta	able II	l - Deriva (e.g., p							posed of convert			y Owned					
Security or Exerci (Instr. 3) Price of	Conversion or Exercise Price of Derivative	ise (Month/Day/Year)	Execution Date, if any		4. Transaction Code (Instr. 8)				6. Date Exerci Expiration Da (Month/Day/Yo		ite	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	Ownersh Form: y Direct (D or Indire (I) (Instr.	wnership orm:	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisa	ıble	Expiration Date	Title	Amount or Number of Shares						
Restricted Stock Units	(1)	08/08/2023			M			3,157	(5)		(5)	Common Stock	3,157	\$0	31,567	,	D		
Restricted Stock	(1)	08/08/2023			М			8,418	(6)		(6)	Common	8.418	\$0	0		D		

Explanation of Responses:

- 1. Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
- $2. \ These \ shares \ of \ the \ Issuer's \ Common \ Stock \ were \ sold \ automatically \ to \ cover \ taxes \ upon \ the \ vesting \ of \ RSUs.$
- 3. The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from \$1.21 to \$1.62, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 4. The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from \$1.21 to \$1.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 5. These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.
- These RSUs vest in a series of six successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

<u>/s/ Robin Harper Cowie</u>

08/10/2023

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.